BAHRAIN AUTHORIZED CLINICAL STUDY OF NASAL SPRAY TO PREVENT MILD COVID-19

Mon 09 August 2021:

Bahrain has approved a clinical trial to evaluate the use of Enovid nasal spray to treat COVID-19 patients in the hopes that it would be approved for use as a COVID-19 preventative and treatment.

The Enovid nasal spray will be tested on people who have been diagnosed with COVID-19 and are experiencing minor symptoms.

Bahrain’s National Health Regulatory Authority (NHRA) made the announcement over the weekend, following a medical report presented by the relevant authorities at the Kingdom’s Ministry of Health.

“The NHRA noted that upon completion of the trial and further analysis of medical data, the spray will be approved for use as prevention and treatment for mild COVID-19 cases and may be sold in pharmacies without prescription,” the Bahrain News Agency reported.

The spray was developed by SaNOtize, a Canadian company, and has been approved for use as a medical device in Bahrain as a patented spray technique in the clinical study.

Nitric oxide is present in the spray, and it has been shown to have antibacterial capabilities in the treatment of bacterial, fungal, and viral illnesses.

“The nasal spray is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs. According to results announced by SaNOtize, early treatment helps reduce the effects of the virus. The study found that patients treated with the spray showed a reduction of around 95% in viral replication in the first 24 hours and more than 99% within 72 hours. No side effects have been recorded,” BNA reported.

———————————————————————————————————————-

FOLLOW INDEPENDENT PRESS:

TWITTER (CLICK HERE)
https://twitter.com/IpIndependent